Oxytocin nasal spray evaluated in a 6-week Phase 2 trial for co-occurring cocaine and opioid use disorders
Background
Co-occurring stimulant use disorder and opioid use disorder (OUD) present significant treatment challenges, often leading to poorer outcomes compared to single substance use disorders. While methadone maintenance therapy (MMT) is effective for OUD, it does not directly address stimulant use, leaving a critical gap in comprehensive care. Oxytocin, a neuropeptide known for its roles in social bonding, stress regulation, and reward pathways, has shown preclinical promise in modulating drug-seeking behaviors. This trial aimed to explore oxytocin's potential to improve outcomes in this complex patient population by leveraging its known effects on social cognition and stress response, which are often dysregulated in addiction.
Study Design
This was a 6-week, randomized, quadruple-blind, placebo-controlled Phase 2 trial involving 42 Veterans diagnosed with co-occurring stimulant use disorder and opioid use disorder, all receiving methadone maintenance therapy (MMT). Participants were randomized to receive either oxytocin nasal spray 40 IU or placebo, self-administered twice daily for the 6-week duration. Weekly visits included collection of urine samples for drug use screening, self-reported drug use assessments, and recording of therapy attendance. At baseline and the final visit, participants completed a Trier Social Stress Test (TSST), with psychophysiological and biomarker data collected to assess stress response.
Results
This Phase 2 randomized controlled trial was completed on February 14, 2020, with an enrollment of 42 participants. However, the provided clinical trial record (NCT03016598) does not contain specific results or outcome data from the study. Therefore, no findings regarding the efficacy or safety of oxytocin nasal spray for co-occurring stimulant use disorder and opioid use disorder can be reported from this record. The study design included primary outcome measures such as changes in drug use (urine toxicology, self-report) and stress biomarkers, but the results for these endpoints are not available in the provided public record.
Key Findings
- Trial completed, but specific results regarding oxytocin's efficacy or safety are not reported in this record.
Why It Matters
The high prevalence and severe consequences of co-occurring stimulant use disorder and opioid use disorder underscore an urgent need for effective, integrated treatments. Current methadone maintenance therapy (MMT) addresses opioid dependence but leaves stimulant use largely unmanaged, contributing to relapse and poorer health outcomes. If future publications from this trial demonstrate efficacy, intranasal oxytocin could represent a novel, non-invasive adjunctive therapy to improve treatment outcomes for this vulnerable population. Successful Phase 2 results would pave the way for larger Phase 3 trials, potentially leading to a new therapeutic option that targets both the neurobiological and psychosocial aspects of co-occurring substance use disorders, enhancing the effectiveness of existing MMT programs.
oxytocin
stimulant-use-disorder
opioid-use-disorder
addiction
clinical-trial
phase-2